Tirabrutinib

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Radiotherapy

1 evidence topic · 1 source

Whole-brain radiotherapy: salvage treatment

“Salvage WBRT may be proposed in radiotherapy-naïve patients” (opens the source at this quote in a new tab)